Article Type
Changed
Fri, 03/15/2019 - 12:32

Bempedoic acid safely dropped LDL cholesterol, and now it’s up for FDA approval. Recent trials advance axial spondyloarthritis therapy. Newer antihyperglycemic drugs have distinctive cardiovascular, kidney benefits. And doctors’ prior authorization burden is increasing.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Topics
Sections

Bempedoic acid safely dropped LDL cholesterol, and now it’s up for FDA approval. Recent trials advance axial spondyloarthritis therapy. Newer antihyperglycemic drugs have distinctive cardiovascular, kidney benefits. And doctors’ prior authorization burden is increasing.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Bempedoic acid safely dropped LDL cholesterol, and now it’s up for FDA approval. Recent trials advance axial spondyloarthritis therapy. Newer antihyperglycemic drugs have distinctive cardiovascular, kidney benefits. And doctors’ prior authorization burden is increasing.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.